Prazer Therapeutics has secured 29 billion won in Series B funding led by Johnson & Johnson. The funds will be used for new drug research and development and global commercialization.
Amount Raised
$21.5 Million
Round Type
Series B
SeoulBiotechnologyHealth CareTherapeuticsInvestors
Description
Biotech startup Prazer Therapeutics has completed a Series B funding round. This investment round was led by Johnson & Johnson's corporate venture capital organization, with participation from several other investors. The secured funds will go towards new drug research and development, focusing on treatments for degenerative brain diseases and cancer. The company aims to collaborate with pharmaceutical companies to accelerate commercialization.
Quick answer
Prazer Therapeutics raised $21.5 Million in a Series B round, dated April 1, 2025. Investors: Premier Partners, K2 Investment, Mirae Asset Capital, Quad Asset Management, STIC Ventures, Company K Partners, Kiwoom Investment and Smilegate Investment. Prazer Therapeutics is based in Seoul, Seoul, South Korea.
- How much did Prazer Therapeutics raise?
- Prazer Therapeutics raised $21.5 Million in a Series B round on April 1, 2025.
- Who invested in Prazer Therapeutics?
- Premier Partners, K2 Investment, Mirae Asset Capital, Quad Asset Management, STIC Ventures, Company K Partners, Kiwoom Investment and Smilegate Investment are named as investors in this round.
- What does Prazer Therapeutics do?
- Prazer Therapeutics is a biotech startup founded in 2019 that develops drugs based on Targeted Protein Degradation (TPD) technology.
- Where is Prazer Therapeutics based and how big is it?
- Prazer Therapeutics is based in Seoul, Seoul, South Korea. Fundz records about 15 employees.
- Who are the decision-makers at Prazer Therapeutics?
- Fundz holds 1 contact at Prazer Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Prazer Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Cellestial Health raised an undisclosed amount (Pre-Seed) on May 9, 2025.
- ImmuneWalk Therapeutics raised $7M (Seed) on May 8, 2025.
- Avammune Therapeutics raised $12M (Series A) on May 7, 2025.
- PAQ Therapeutics raised $39M (Series B) on May 7, 2025.
- Paradigm Therapeutics raised $13M (Funding Round) on May 6, 2025.
- Azora Therapeutics, Inc. (DE) raised $4.8M on May 2, 2025.
Who to call at Prazer Therapeutics, and when
A new round usually means Prazer Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Prazer Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Prazer Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Prazer Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Prazer Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansPrazer Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.